C caspase 7

Manufactured by Cell Signaling Technology

Sourced in United States

C-caspase 7 is a recombinant protein that represents the cleaved, active form of caspase 7. Caspase 7 is a member of the cysteine-aspartic acid protease (caspase) family, which play essential roles in the execution of the cell apoptosis (programmed cell death) pathway.

Automatically generated - may contain errors

Lab products found in correlation

Spelling variants of this product

Caspase-7 (145 citations) Caspases (2 citations)

2 protocols using c caspase 7

DNA Damage Response Signaling Pathway

Check if the same lab product or an alternative is used in the 5 most similar protocols

Monoclonal and polyclonal antibodies specific for the following molecules were used: γ-H2AX, caspase 3, c-caspase 3, caspase 7, c-caspase 7, CHK2, and pCHK2 (Cell Signaling Technology, Danvers, MA); LMP-2, MECL-1, and PARP (Santa Cruz Biotechnology, Santa Cruz, CA). Pre-designed and validated CHK2 siRNA (S22119, S22120, S22121) and control siRNA were purchased from ThermoFisher Scientific (Waltham, MA).

Liu W., Chen J., Tamayo A.T., Ruan C., Li L., Zhou S., Shen C., Young K.H., Westin J., Davis R.E., Hu S., Medeiros L.J., Ford R.J, & Pham L.V. (2017). Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma. Oncotarget, 9(1), 346-360.

+ Open protocol

+ Expand

Evaluation of EGFR-Signaling Pathway Inhibitors

Check if the same lab product or an alternative is used in the 5 most similar protocols

Gefitinib was provided by Selleck (ZD1839, Houston, TX, USA). Erlotinib (#S7786) was also provided by Selleck (Houston, TX, USA). The primary antibodies STAT3 (#12640), pY705-STAT3 (9145S), pY701-STAT1 (#9167), STAT5 (#25656) , phospho694-STAT5 (#9351), EGFR (4267S), phospho-EGFR (3777S), JAK2 (#3230), phospho-JAK2 (#3771), AKT (#4685), p-AKT (#4060), c-Myc (#5605), and c-Caspase-7 (#9491) were from Cell Signaling Technology (Danvers, MA, USA). STAT1 (10144-2-AP) was from Proteintech (Wuhan, Hubei, China). Bcl-2 (sc-7382), Bcl-xL(sc-8392) and β-actin (sc-47778) were from Santa Cruz (Dallas, TX, USA). The secondary antibodies were HRP-conjugated anti-rabbit IgG, anti-mouse IgG (Abcam, Cambridge, UK). EGF (AF-100-15-500) was provided by PEPROTECH (Suzhou, China).

Zheng Q., Dong H., Mo J., Zhang Y., Huang J., Ouyang S., Shi S., Zhu K., Qu X., Hu W., Liu P., Wang Y, & Zhang X. (2021). A novel STAT3 inhibitor W2014-S regresses human non-small cell lung cancer xenografts and sensitizes EGFR-TKI acquired resistance. Theranostics, 11(2), 824-840.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!